AEON Biopharma, Inc. has initiated a public offering of common stock and warrants

From GlobeNewswire: 2025-01-03 20:02:00

AEON Biopharma, Inc. has initiated a public offering to sell units consisting of common stock shares and warrants. Aegis Capital Corp. has a 45-day option to purchase additional shares to cover over-allotments. The net proceeds will be used for general corporate and working capital needs. The offering is subject to market conditions, and Aegis Capital Corp. is the sole book-running manager. The offering is being made pursuant to an effective shelf registration statement. AEON is focused on developing ABP-450, a botulinum toxin complex for debilitating medical conditions. For more information, visit www.aeonbiopharma.com.



Read more at GlobeNewswire: AEON Biopharma, Inc. Announces Launch of Proposed Public